SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
liv2675-sup-0001-FigureS1.tifimage/tif246KFig. S1. Prognostic significance of intratumoral FoxP3+ Tregs in HCC patients in the intermediate or advanced stages. The cumulative overall survival (OS) and time to recurrence (TTR) of HCC patients were estimated using the Kaplan–Meier method and compared by the log-rank test. Patients with high-FoxP3+ Treg levels (green lines) had similar TTR (A, = 0.182) and OS (B, = 0.756) compared with individuals with low FoxP3+ Treg density (blue lines).
liv2675-sup-0002-FigureS2.tifimage/tif5107KFig. S2. Prognostic significance of tumor-infiltrating CD8+ T cells and the balance of FoxP3+ Tregs/CD8+ T cells in HCC patients with different stages. (A–F) Prognostic significance for CD8+ T cells; A and D showed TTR/OS for all patients with HCC; B and E displayed TTR/OS for HCC patients in the early stage; C and F illustrated TTR/OS for HCC patients in the intermediate or advanced stages. (G–L) Prognostic significance for the balance of FoxP3+ Tregs/CD8+ T cells; G and J showed TTR/OS for all patients with HCC; H and K displayed TTR/OS for HCC patients in the early stage; I and L illustrated TTR/OS for HCC patients in the intermediate or advanced stages. Group1, low Tregs and low CD8+ T cells; Group 2, low Tregs and high CD8+ T cells; Group 3, high Tregs and low CD8+ T cells; Group 4, high Tregs and high CD8+ T cells.
liv2675-sup-0003-FigureS3.tifimage/tif114KFig. S3. The significance in the absolute number of circulating FoxP3+ Tregs (× 106 cells/L). (A) The absolute number of circulating FoxP3+ Tregs in HCC, CHB patients and normal controls (NC). **= 0.008. (B) The absolute number of FoxP3+ Tregs in different stages HCC patients compared with Tregs in NC, CHB respectively. *< 0.05,***= 0.001.
liv2675-sup-0004-FigureS4.tifimage/tif235KFig. S4. Prognostic significance of circulating FoxP3+ Tregs in HCC patients in the intermediate or advanced stages. The cumulative overall survival (OS) and time to recurrence (TTR) of HCC patients were estimated using the Kaplan–Meier method and compared by the log-rank test. No difference of TTR (A, = 0.966) and OS (B, = 0.392) was found in patients with high frequency of FoxP3+ Tregs (green lines) or low FoxP3+ Tregs (blue lines).
liv2675-sup-0005-FigureS5.tifimage/tif1040KFig. S5. Prognostic significance of effector CD4+CD25+FoxP3 Tregs in HCC patients. A and D showed TTR/OS for all patients with HCC; B and E displayed TTR/OS for HCC patients in the early stage; C and F illustrated TTR/OS for HCC patients in the intermediate or advanced stages.
liv2675-sup-0006-FigureS6.tifimage/tif158KFig. S6. The frequency of circulating CD4+CD25+FoxP3+ Tregs related to tumor-infiltrating FoxP3+ Tregs. A high degree of linear correlation was observed in CHB, HCC in early stages (Stage 0, A) and intermediate stage (Stage B), but only a weak correlation was found in the advanced stage (Stage C).
liv2675-sup-0007-FigureS7.tifimage/tif137KFig. S7. The absolute number of circulating CD4+CD25+FoxP3+ Tregs (× 106 cells/L) corrrelated with tumor-infiltrating FoxP3+ Tregs.
liv2675-sup-0008-TableS1.docxWord document15KTable S1. Univariate and multivariate analyses of prognosis factors associated with overall survival and time to recurrence in patients with HCC in group A2
liv2675-sup-0009-TableS2.docxWord document15KTable S2. Univariate and multivariate analyses of prognosis factors associated with overall survival and time to recurrence in patients with HCC in group B2.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.